Table 1.
Baseline characteristics of study population
| Study | n | Age (Years) | Viral Status (C/B/C+B) | Alcohol Intake@(No/Yes) | Tumor Size (mm) | Tumor no | Child Pugh (A/B) | Treatment (Surgery/Local) | Follow up |
|---|---|---|---|---|---|---|---|---|---|
| Mizuta et al. | |||||||||
| Treatment |
32 |
63.3 ± 7.5 |
28/3/1 |
10/22 |
17.7 ± 5.1 |
1.5 ± 0.9 |
26/6 |
1/31 |
28.9 (± 8.3) |
| Control |
29 |
64.5 ± 6.7 |
26/2/1 |
3/26 |
19.4 ± 6.9 |
1.5 ± 0.7 |
22/7 |
3/26 |
27.7 (± 8.6) |
| Kakizaki et al. | |||||||||
| Treatment |
30 |
69.1 ± 5.9 |
30/0/0 |
6/24 |
20.4 ± 11.6 |
19/11 |
22/8 |
4/26/0 |
36 |
| Control |
30 |
69.0 ± 7 |
30/0/0 |
3/27 |
25.0 ± 9.4 |
22/8 |
22/8 |
7/23/0 |
36 |
| Hotta et al. | |||||||||
| Treatment |
21 |
|
14/6 |
|
18/3* |
15/6 |
15/6 |
2/19 |
|
| Control |
21 |
|
3/19 |
|
18/6* |
12/12 |
12/12 |
2/22 |
|
| Yoshiji et al. | |||||||||
| Treatment |
18* |
62.8 ± 7.4 |
15/0 |
8/10 |
17.9 ± 9.2 |
1.6 ± 0.9 |
16/2 |
0/18 |
36 |
| Control |
25 |
60.5 ± 8.5 |
1/3 |
12/13 |
18.7 ± 9.5 |
1.6 ± 0.9 |
20/5 |
0/25 |
36 |
| Yoshida et al. | |||||||||
| Treatment# |
367 |
68.6 ± |
305/38 |
140/227 |
19.9 ± 7.6 |
1.4 ± 0.7 |
323/44 |
14/353 |
37 |
| Control | 181 | 7.9 | 150/20 | 79/102 | 20.3 ± 7.6 | 1.4 ± 0.7 | 154/27 | 7/174 | 37 |
*The data in the treatment group of Yoshiji et al. is restricted to 18 patients to exclude 19 patients who received ACE-inhibitors and 25 patients who received a combination of ACE-Inhibitors and Vitamin K2.
@Mizuta et al. and Yoshiji et al. have defined heavy alcoholism by consumption greater than 40 grams/day whereas Kakizaki et al. has defined it as greater than 65 gm/dl. Yoshida et al. has defined at as consumption greater than thrice days per week regardless of the quantity.
#The treatment group in the study of Yoshida et al. compromised 367 patients, of whom 182 received drug at a dosage of 45 mg/day whereas the remaining 185 at 90 mg/day. The dosages in all the other studies is 45 mg/day.